Form 4: VTV Therapeutics Director, Daniel K. Spiegelman, Acquires Stock Options

Director Daniel K. Spiegelman acquired stock options in VTV Therapeutics Inc. on June 25, 2024.

Summary

• On June 25, 2024, Daniel K. Spiegelman, a director of vTv Therapeutics Inc., acquired 6,000 stock options.
• The options have an exercise price of $17.22.
• The options vest monthly over a three-year period following the grant date and expire on June 25, 2034.
• Following the transaction, Spiegelman directly owns 6,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be seen as a slightly positive sign of confidence but doesn't provide strong positive or negative signals.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholders, as it may align the director's interests with those of the shareholders.

Key Dates